Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2020-03-10 Board/Management Inform…
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 10, 2020, reporting the event that Dr. Hongbo Zhai has joined the company's Science Advisory Board. The content is an announcement of a management-related event, specifically a change in the company's advisory board membership. There are no financial statements or detailed financial data included. The document includes a press release as an exhibit. Given that it announces a change in senior management/advisory board, the appropriate classification is Board/Management Information (MANG). The document length is 3367 characters, which is short and consistent with an announcement rather than a full report.
2020-03-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 4, 2020, by Moleculin Biotech, Inc. It announces the issuance of a video letter to shareholders from the CEO, which includes an update on current activities and corporate strategy. The document references a press release and a shareholder letter presentation as exhibits. The content is primarily an announcement of a shareholder communication and corporate update rather than a full financial report or detailed earnings release. The document length is 3503 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories like earnings releases or annual reports.
2020-03-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 19, 2020. It announces an event related to an independent assessment of cardiotoxicity absence in clinical trials for a drug. The document includes a press release as an exhibit. The content is an announcement of a specific event rather than a full financial report, audit, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is 3728 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-02-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 18, 2020. It announces the issuance of a press release regarding final clinical trial data for a drug treatment, which is attached as an exhibit. The content is an announcement of an event (clinical trial results release) rather than a full financial report or detailed management discussion. The document length is 3730 characters, which is relatively short and mainly serves to announce the press release. There are no financial statements or detailed financial data included. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories like Earnings Release or Annual Report.
2020-02-18 English
SCHEDULE 13G
Major Shareholding Notification
2020-02-11 English
MOLECULIN BIOTECH, INC.
Major Shareholding Notification
2020-02-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.